NanoXplore Inc. to Announce Third Quarter Results Conference Call on Tuesday May 17, 2022, and the Nomination of its Director of Investor Relations

NanoXplore Inc. (TSX: GRA and OTCQX: NNXPF) ("NanoXplore") is pleased to hold a conference call to discuss the results of its third quarter ended March 31, 2022, on Tuesday, May 17, 2022, at 8:30 a.m. Eastern Time. The financial results will be released on Monday, May 16, 2022, after the market close.

Details of the Q3 Conference Call

When : May 17, 2022, at 8:30 a.m. Eastern Time

Dial-in number : 1-866-696-5894 (toll free Canada and US) or 416-340-2217 (Toronto area)

Participant code: 4177433#.

Please call 10 minutes prior to the start of the conference call.

There will be a rebroadcast of the call available by dialing 1-800-408-3053 (toll free Canada and US) or 905-694-9451 and enter the participant code 1955519#. The rebroadcast will be available until May 23, 2022.

Nomination of Martin Gagné, Director of Investor Relations

In addition, NanoXplore announced the appointment of Martin Gagné to a newly created position of Director of Investor Relations, effective May 2, 2022. In his role, Martin will oversee all aspects of investor relations activities and will report directly to the CEO and founder Soroush Nazarpour. As Director of Investor Relations, he will be responsible for the development, implementation, and management of a strategic plan for investor relations that will maximize NanoXplore's visibility in the financial community.

Martin brings more than 15 years of experience in the investment industry and holds a CPA and CFA designations. Prior to joining NanoXplore, Martin worked as a senior analyst and Portfolio Manager for asset management firms covering multiple industries in the Canadian and US Equity markets.

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in transportation and industrial markets. The Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal.

For further information:

Investors and media

Martin Gagné
Director of Investor Relations
martin.gagne@nanoxplore.ca
Tel: 1 438 476 1927


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News